Portfolio > Antoxis

Antoxis is a biotechnology company taking a rational approach to the design and synthesis of novel, cell-targeted antioxidants to limit free radical damage in clinical conditions of high, unmet medical need. Its current focus is in relation to diseases of ageing, such as diabetes, Parkinson's and Alzheimer's, as well as stem cell applications. The company has developed and patented novel compound libraries based on its extensive knowledge of the structure-activity relationships of plant antioxidants, such as flavonoids.

Antoxis' mission is to impart key drug attributes to these natural molecular scaffolds essential for use in a therapeutic context. The company's platform technologies target high-potency antioxidants to critical areas of the cell susceptible to oxidative damage and aim to enhance transport across the blood-brain barrier for CNS indications. AO-1-530 has demonstrated potent protection in a number of cell-based oxidative stress models, including neuronal cells and mouse embryonic stem cells, with a large amplification in efficacy over its natural flavonoid counterpart.

Compounds of this class have the ability to vector the antioxidant functional to the mitochondrial compartment of the cell thereby making them ideal candidates to tackle the cycle of oxidative stress-mitochondrial dysfunction-apoptosis that is a central feature of a number of disease processes. Antoxis has established a pre-clinical programme to look at protection in disease relevant models and stem cell treatments and is working with Pharma, the NHS and academic partners to advance these into the clinic.

Latest News

NovaBiotics secures an additional £3.0 million investment from Woodford Investment Management
3rd March 2017

Commercial Collaboration Deal for (Oral) Lynovex®
5th August 2016

NovaBiotics Announces New Data on Cysteamine (Nylexa™)
18th June 2016

NovaBiotics Highlights Importance of Co-ordinated Approach to Antimicrobial Resistance
7th June 2016

NovaBiotics Wins Investment of the Year Award
5th February 2016

Lynovex® Activity in CF sputum & Against the Emerging CF Pathogen, Mycobacterium abscessus
12th August 2015

Phase IIa clinical study results for NovaBiotics' Lynovex® presented at the 38th Annual European Cystic Fibrosis Symposium
12th June 2015

Launch of the BEAM Alliance
9th June 2015

NovaBiotics Quoted in "What Investment" on 11 February
11th February 2015

NovaBiotics Raises £5.0 million in a Private Placement from Woodford Investment Management
19th January 2015

NovaBiotics' Dr Deborah O'Neil Named EY UK Health Products & Services Entrepreneur of 2014
7th October 2014

Showcases increasing investor interest in the global stem cell sector
22nd September 2014

NovaBiotics Receives Orphan Drug Status from the US Food and Drug Administration (FDA) for Lynovex®
16th September 2014

Scotland's Pharmacells Group creates 12 new jobs at BioCity Scotland following acquisition by Precious Cells Group, London
18th August 2014

Precious Cells Biobank Acquires Stem Cell Technology Leader Pharmacells Group
25th July 2014